These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38451423)

  • 1. Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.
    Sun R; Bustamante M; Gurusamy VK; Lebwohl M; Gottlieb AB; Mease PJ; Deodhar A; Bao W; Mendelson M; Porter B; Chand D; Dong V
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):729-743. PubMed ID: 38451423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
    Sticherling M; Nikkels AF; Hamza AM; Kwong P; Szepietowski JC; El Sayed M; Ghislain PD; Khotko AA; Patekar M; Ortmann CE; Forrer P; Papanastasiou P; Keefe D
    Am J Clin Dermatol; 2023 Sep; 24(5):821-835. PubMed ID: 37341961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.
    Deodhar AA; Combe B; Accioly AP; Bolce R; Zhu D; Gellett AM; Sprabery AT; Burmester GR
    Ann Rheum Dis; 2022 Jul; 81(7):944-950. PubMed ID: 35393269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study.
    Wu CY; Wang Q; Shi J; Zhang XY; Du R; Gu JR; Liu QH; Yu J; Xu JW; Zhang YJ; Zhu H; Li MT; Zeng XF
    Rheumatol Ther; 2023 Dec; 10(6):1609-1622. PubMed ID: 37768505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
    Langley RG; Sofen H; Dei-Cas I; Reich K; Sigurgeirsson B; Warren RB; Paul C; Szepietowski JC; Tsai TF; Hampele I; You R; Charef P; Papavassilis C
    Br J Dermatol; 2023 Feb; 188(2):198-207. PubMed ID: 36763857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.
    Rubin DT; Modesto I; Vermeire S; Danese S; Ng SC; Kwok KK; Koram N; Jones TV
    Aliment Pharmacol Ther; 2022 Feb; 55(3):302-310. PubMed ID: 34626429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials.
    Mease PJ; Gladman DD; Gomez-Reino JJ; Hall S; Kavanaugh A; Lespessailles E; Schett G; Paris M; Delev N; Teng L; Wollenhaupt J
    ACR Open Rheumatol; 2020 Aug; 2(8):459-470. PubMed ID: 32710493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
    van de Kerkhof PC; Griffiths CE; Reich K; Leonardi CL; Blauvelt A; Tsai TF; Gong Y; Huang J; Papavassilis C; Fox T
    J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
    JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
    Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
    Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
    Gordon KB; Langley RG; Warren RB; Okubo Y; Rosmarin D; Lebwohl M; Peterson L; Madden C; de Cuyper D; Davies O; Thaçi D
    Br J Dermatol; 2024 Mar; 190(4):477-485. PubMed ID: 37950894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
    Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
    Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials.
    Chen YC; Yoo DH; Lee CK; Li KJ; Won JE; Wu WS; Zhong J; Nicolay C; Walls CD; Tanaka Y
    Int J Rheum Dis; 2020 Jan; 23(1):65-73. PubMed ID: 31729189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
    Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
    Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
    Lebwohl M; Deodhar A; Griffiths CEM; Menter MA; Poddubnyy D; Bao W; Jehl V; Marfo K; Primatesta P; Shete A; Trivedi V; Mease PJ
    Br J Dermatol; 2021 Nov; 185(5):935-944. PubMed ID: 33829482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
    Lebwohl MG; Merola JF; Rowland K; Miller M; Yang YW; Yu J; You Y; Chan D; Thaçi D; Langley RG
    Br J Dermatol; 2023 Jul; 189(1):42-52. PubMed ID: 37022762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.
    Burmester GR; Coates LC; Cohen SB; Tanaka Y; Vranic I; Nagy E; Lazariciu I; Chen AS; Kwok K; Fallon L; Kinch C
    Rheumatol Ther; 2023 Oct; 10(5):1255-1276. PubMed ID: 37458964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
    Gottlieb AB; Deodhar A; Mcinnes IB; Baraliakos X; Reich K; Schreiber S; Bao W; Marfo K; Richards HB; Pricop L; Shete A; Trivedi V; Keefe D; Papavassilis CC; Jagiello P; Papanastasiou P; Mease PJ; Lebwohl M
    Acta Derm Venereol; 2022 Apr; 102():adv00698. PubMed ID: 35146532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.
    Deodhar AA; Miceli-Richard C; Baraliakos X; Marzo-Ortega H; Gladman DD; Blanco R; Das Gupta A; Martin R; Safi J; Porter B; Shete A; Rosenbaum JT
    ACR Open Rheumatol; 2020 May; 2(5):294-299. PubMed ID: 32352653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.